APPENDIX

Lifetime Medical Costs Attributable to Sickle Cell Disease among Non-Elderly Individuals with Commercial Insurance

Kate M. Johnson, PhD,¹ Boshen Jiao, MPH¹, Scott D. Ramsey MD, PhD^{1,2}, M. A. Bender, MD³, Beth Devine, PhD, PharmD, MBA¹, Anirban Basu, PhD^{1,4,5}

Affiliations:

- 1. The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Department of Pharmacy, University of Washington
- 2. Division of Public Health Sciences and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center
- 3. Department of Pediatrics, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Research Center
- 4. Department of Health Services, University of Washington
- 5. Department of Economics, University of Washington

Calculation of the KMSA estimator

Survival-adjusted SCD-attributable total and out-of-pocket costs were calculated using the following equation,

$$SCD-attributable \ costs_i = \sum S_i^{SCD} C_i^{SCD} - \sum S_i^{CO} C_i^{CO}$$

Where *S* is the probability of having survived to age *i* and *C* is the annual costs of survivors at age *i* for individuals with SCD (*SCD*) and matched controls (*CO*). The overall burden of SCD-attributable costs captured in Equation 1 encompasses both the intensity of excess costs incurred by surviving SCD individuals compared to matched controls and the cost-savings due to having higher mortality rates than matched controls⁵⁰. An advantage of using the KMSA estimator is that it allows for decomposition of the total excess burden into its component intensity and mortality effects. Equation 1 can be rewritten as:

$$SCD-attributable \ costs_i = \sum S_i^{SCD} (C_i^{SCD} - C_i^{CO}) + \sum C_i^{CO} (S_i^{SCD} - S_i^{CO})$$

where the first part is the intensity effect, and the second part is the mortality effect. The variance of the KMSA estimator was obtained using the delta method, which determines the variance of the product of two conditionally independent stochastic quantities:

$$Var(S * C) = Var(S) * Var(C) + Var(S) * E(C)^{2} + Var(C) * E(S)^{2}$$

We calculated Var(C) using 1000 individual-level clustered bootstrapped replicates. To calculate Var(S), we conducted binomial sampling with mean survival probabilities applied to 1,950 individuals (the starting cohort size in Lubeck et al.²⁷). We calculated age-specific survival probabilities for males and females in 1000 bootstrap replicates.

Statistical Model of Costs for Survivors

We used a quasi-likelihood approach with generalized linear models and flexible link and variance functions to model total health care costs and OOP costs (in separate models)²⁴. Goodness of fit was assessed using raw-scale residual-based analysis²⁵. The regression results for total health care costs are shown below:

Extended GEE v Optimization: Variance: Link: Std Errors:	with Quadratic Fisher's Scor (theta1*mu + (mu^lambda - Robust	: Variance A Ying theta2*mu^2 1)/lambda	unction	No of Residu	obs = waldf =	90048 90012
у	Coefficient	Std. err.	Z	P> z	[95% conf.	interval]
v	+ 					
, rind1	- 1584537	0592894	-2.67	0.008	- 2746587	0422487
rind2	0365767	.0589353	-0.62	0.535	1520877	.0789343
rind3	.0446337	.0566887	0.79	0.431	0664741	.1557415
rind4	.1656652	.0733571	2.26	0.024	.0218879	.3094426
planind1	2464324	.0558485	-4.41	0.000	3558935	1369713
planind2	1666441	.0687521	-2.42	0.015	3013957	0318926
planind3	2183008	.0423459	-5.16	0.000	3012972	1353043
planind4	1892055	.0452074	-4.19	0.000	2778104	1006005
planind5	0222611	.0390545	-0.57	0.569	0988065	.0542843
planind6	3680419	.0640599	-5.75	0.000	493597	2424869
planind7	0733834	.0607798	-1.21	0.227	1925096	.0457429
vearind1	3395468	.0452941	-7.50	0.000	4283217	2507719
vearind2	2243535	.0433402	-5.18	0.000	3092987	1394084
vearind3	1396276	.0423644	-3.30	0.001	2226603	0565949
vearind4	1367749	.0541626	-2.53	0.012	2429316	0306182
vearind5	0785478	.0420439	-1.87	0.062	1609523	.0038568
vearind6	0840524	.0404675	-2.08	0.038	1633671	0047376
vearind7	0464538	.0569081	-0.82	0.414	1579916	.065084
vearind8	031775	.0460317	-0.69	0.490	1219955	.0584454
vearind9	.0721245	.0525026	1.37	0.170	0307788	.1750277
vearind10	.0475811	.0439127	1.08	0.279	0384862	.1336484
vearind11	.0719153	.0435052	1.65	0.098	0133534	.1571841
ageind1	0725437	.0486554	-1.49	0.136	1679066	.0228193
ageind2	.2665828	.0556287	4.79	0.000	.1575527	.375613
ageind3	.3792646	.0807021	4.70	0.000	.2210914	.5374378
ageind4	.2114908	.1082412	1.95	0.051	000658	.4236397
ageind5	.2180714	.1545759	1.41	0.158	0848918	.5210346
ageind6	.4251936	.1873353	2.27	0.023	.0580232	.792364
run agec	.0004878	.0039118	0.12	0.901	0071793	.0081549
run agec2	.0001211	.0001026	1.18	0.238	00008	.0003221
female1	0836802	.0201018	-4.16	0.000	123079	0442813
Nmonths	.0925765	.0037198	24.89	0.000	.0852858	.0998673
_cons	-1.063492	.1315447	-8.08	0.000	-1.321315	8056687
	+					
lambda						
_cons	.6367459	.041736	15.26	0.000	.5549448	.7185469
	+ I					
thetal	0 0040545	1 541405	0.04	0.075	2 000404	7 747407
_cons		1.541485	0.21	0.835	-2.699404	3.34310/
+hoto)	+ I					
checaz		2 007054	2 52	0 011	2 227442	17 5462
_cons	9.000000	7.26/221	2.00	0.011	2.22/412	17.5403

The regression results for OOP costs are shown below:

Extended GEE v Optimization:	vith Quadratic Variance Function Fisher's Scoring			No of Residu	obs = aldf =	90048 90012
Variance:	(theta1*mu +	theta2*mu^2)			
Link:	(mu^lambda -	1)/lambda	·			
Std Errors:	Robust					
у	Coefficient	Std. err.	z	P> z	[95% conf.	interval]
	+					
у						
rind1	5305903	.0407225	-13.03	0.000	610405	4507756
rind2	1782236	.0402637	-4.43	0.000	257139	0993082
rind3	.0843788	.0398691	2.12	0.034	.0062367	.1625209
rind4	3197721	.0472745	-6.76	0.000	4124284	2271158
planind1	7704909	.0341067	-22.59	0.000	8373388	703643
planind2	6758925	.0419552	-16.11	0.000	7581232	5936618
planind3	9391512	.0292135	-32.15	0.000	9964086	8818939
planind4	5870817	.0284457	-20.64	0.000	6428344	5313291
planind5	2963437	.0263227	-11.26	0.000	3479353	244752
planind6	-1.221872	.0485045	-25.19	0.000	-1.31694	-1.126805
planind7	2453794	.028846	-8.51	0.000	3019164	1888423
vearind1	3409517	.0312783	-10.90	0.000	402256	2796474
vearind2	283074	.0347462	-8.15	0.000	3511753	2149726
vearind3	2242791	.0273852	-8.19	0.000	2779531	1706052
vearind4	163319	.0272298	-6.00	0.000	2166885	1099495
vearind5	0805378	.0288702	-2.79	0.005	1371223	0239533
vearind6	0784907	.0264543	-2.97	0.003	1303401	0266413
vearind7	0521152	.0305403	-1.71	0.088	1119732	.0077427
vearind8	0552346	0291139	-1.90	0.058	- 1122967	.0018276
vearind9	1684591	.0365773	4.61	0.000	.096769	2401492
vearind10	.1310825	.0322429	4.07	0.000	.0678876	1942774
vearind11	1585071	.0271914	5.83	0.000	1052129	2118014
ageind1	0156832	0438837	0.36	0 721	- 0703274	1016938
ageind2	1327992	0321753	4 13	0 000	0697368	1958616
ageind3	2771352	0/81709	5 75	0.000	1827219	3715/8/
ageind	3333095	067/93/	1 9/	0.000	20102/212	16559/1
ageind5	29/9299	0895962	3 29	0.000	11932/6	4705352
ageind6	3/6982/	10/9265	3 31	0.001	1/13301	5526346
nun agec	0030738	0022892	-1 34	0.001	- 0075605	001/128
nun agec	0001/05	0022052	2 50	0.175	0000322	00014120
fomalo1	0236897	0136021	-1 74	0.015	- 0503/9/	0002000
Nmonths	0012/6	0028707	31 69	0.002	0856018	0068001
NIIIOTETIS	6830/81	0011074	7 51	0.000	8625152	5053800
	+	.09110/4	-7.51		0025152	
lambda						
_cons	.4362815	.0411676	10.60	0.000	.3555945	.5169685
theta1						
_cons	.8185535	.6356063	1.29	0.198	427212	2.064319
theta2						
_cons	3.184539	1.615583	1.97	0.049	.0180536	6.351024

Table 1: Raw total costs and o	ut-pocket-costs	for individuals	with SCD.	Costs are	not model-
estimated and shown as mean (standard error).				

Age (years)	Individuals with SCD			
	Females	Males		
	TOTAL MEDICAL COSTS			
0-5	\$24,894 (1,388)	\$32,098 (1,479)		
6-12	\$30,156 (1,386)	\$31,404 (1,066)		
13-18	\$37,364 (1,295)	\$43,676 (4,108)		
19-24	\$41,720 (1,435)	\$43,054 (1,751)		
25-34	\$34,168 (767)	\$36,529 (1,481)		
35-54	\$35,850 (698)	\$39,808 (1,736)		
55-64	\$47,299 (1,529)	\$46,320 (1,746)		
	OUT-OF-POCKET COSTS			
0-5	\$1,230 (93)	\$1,305 (30)		
6-12	\$1,143 (25)	\$1,216 (24)		
13-18	\$1,240 (28)	\$1,280 (29)		
19-24	\$1,394 (30)	\$1,354 (38)		
25-34	\$1,447 (38)	\$1,327 (29)		
35-54	\$1,355 (18)	\$1,326 (47)		
55-64	\$1,398 (24)	\$1,393 (32)		







Figure 2: Estimated total costs and OOP costs among surviving SCD individuals smoothed over age. 95% confidence limits were

estimated using 1000 individual-level clustered bootstrap replicates.



Figure 3: Digitized survival curves for SCD individuals and matched controls by sex.